Get started
Lexicon Pharmaceuticals, Inc.Lexicon Pharmaceuticals, Inc.Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals, Inc.

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Options

LXRX trade ideas

LXRX PENNY BIOTECH SHORT SETUPNASDAQ:LXRX LXRX has gained over 100% in the past month However it appears to be forming a double top in a potential short trade setup on the two hour chart. The K/D crossover on the hot RSI oscillator provides confirmation. Short Sale Volume is rising in the past two days. Findamentals - LXRX has a new medication for heart failure a common medical problem with a massive market It recently launched a public offering to raise capital to fund general operations and in doing so diluted the share holders. The good news is it is unlikely to do another in the near term. An entry would be at the current price with a stop loss above the highest volume bar on the profile. The first target is the POC of the volume profile about a 15% price drop . The second target is the pivot low on August 1st for another 15% drop. Taking of 1/2 at each target yields an expected 23% return over a period of about 5 trading days since drops are faster than rises. The call options of mid September have low volumes so I will not consider them.
NASDAQ:LXRXShort
by AwesomeAvani
LXRX - long - Cup with HandleLexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drugs candidates are LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain; and sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for heart failure and type 1 diabetes. This is not a financial advice! Upcoming catalysts 08/31/2024 Block buys and Insider buys recently Rel. Vol. on 03/12/2024 at 7.45 Cup with Handle ist forming We need to stay in a bullish overal sentiment of the market. If we see a corretion, this play might doesn't work. Keep an eye on 3.7 level, needs to get broken for a further upmove. You can take partial profits at these levels if u want to lock in gains. SL under 1.8 TPs approx. 5.3 Most info on the chart. Trade carefully!
NASDAQ:LXRXLong
by meitshels_smell_trades
$LXRX - Inpefa FDA Approved - Inverse H&S - BOOM BOOM ROOMThis could be a game changer. Marketcap of Lexicon Pharm that produces Inpefa is only $538M with plenty of cash on hand. Competitor drugs Jardiance from NYSE:LLY and Farxiga from NASDAQ:AZN did over $6B and $4B revenue respectively in 2022 and expected to grow quite a bit over the next few years. Inpefa received FDA approval and was rolling out commercialization and sales at the end of June. This should be a fun ride! This is my own opinion and should not be taken as financial advice. Own your own trades.
NASDAQ:LXRXLong
by Croaking
LXRX | InformativeNASDAQ:LXRX Technical Analysis for LXRX: If LXRX breaks above the bullish line of $4.00, it may indicate a bullish signal and suggest potential upward price movement. In this scenario, the target prices (TP) could be set at $4.50 and $6.00 as bullish targets. Conversely, if LXRX breaks below the bearish line of $2.87, it may suggest a bearish signal and imply potential downward price movement. The target prices (TP) for the bearish scenario could be set at $2.33 and $1.70. It is important to consider other technical factors, such as the formation of a double top, Elliott Wave theory movements, and RSI overbought condition, which may indicate a potential pullback before the breakout. The double top pattern suggests a potential reversal, while Elliott Wave theory can provide insights into the price's wave-like movements. These factors should be taken into account when analyzing LXRX's price action. And the pull back price target could be at 3.29$ area. Fundamental Analysis for LXRX: LXRX is a biopharmaceutical company that develops innovative therapies for patients with metabolic diseases. The company's pipeline includes potential treatments for diabetes, hypercholesterolemia, and fatty liver disease. LXRX leverages its expertise in lipid metabolism to address unmet medical needs and improve patient outcomes. LXRX's financial performance and market position are influenced by the success of its drug candidates in clinical trials and the potential for regulatory approval. Positive clinical trial results and successful regulatory milestones can significantly impact the company's stock price. It is important to consider potential risks associated with the biopharmaceutical industry, including the uncertain outcome of clinical trials, regulatory challenges, and competitive pressures. The success of LXRX's drug candidates depends on factors such as efficacy, safety, and market acceptance. Additionally, changes in healthcare policies and reimbursement practices could affect the commercial potential of LXRX's products. However, LXRX's focus on metabolic diseases and its pipeline of potential therapies position the company for potential growth opportunities. The successful development and commercialization of its drug candidates could lead to increased market share and revenue growth in the long term. Please note that this analysis is based on the available information and market conditions at the time of writing. It is important to conduct further research and analysis before making any investment decisions.
NASDAQ:LXRX
by shkspr
$LXRX A Roar Of ApprovalThe first step towards profitability for biotech companies is FDA approval since it allows these companies to start realizing revenues from their treatments. One of the biotech stocks that is set to earn revenues for the first time is Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) whose heart failure treatment was approved by the FDA last Friday. Although LXRX stock climbed 21% in the lead-up to FDA approval, the stock cooled down and is back to where it was before the approval – making it a biotech stock worth buying ahead of its first revenues. LXRX Fundamentals Since having a revenue-generating product adds value to any company, LXRX is on the same trajectory since its flagship drug INPEFA (sotagliflozin) for heart failure was approved by the FDA last Friday after hours. INPEFA is scheduled to be available for purchase in June which means that LXRX is set to realize its first revenues in Q3 2023. As generating revenues should increase the value of the company, the LXRX stock should increase to reflect this added value. The marketplace for heart failure medications is vast and growing at an explosive rate. Currently, the market is valued at around $6.7 billion and is expected to grow at a CAGR of 7.6% from 2023 to 2031 reaching approximately $13.5 billion. This high growth rate indicates that there is high demand for heart failure medication in the market especially since around 6.7 million Americans suffer from heart failure. That number is expected to grow to around 8 million in 2030 which shows that there is no shortage in demand for heart failure treatments. With this in mind, LXRX expects the wholesale price of INPEFA to be on par with existing branded heart failure medications. One of INPEFA’s most prominent competitors is Jardiance which was developed by Eli Lilly and Company (NYSE: LLY) and Boehringer Ingelheim. Jardiance current list price is $$570.48 for a month’s supply and INPEFA presents a unique proposition in heart failure – especially considering the drug’s differentiated benefit in hospitalized patients compared with existing treatments. Based on this, Piper Sandler analyst Yasmeen Rahimi expects INPEFA to generate $112 million in revenues by 2025 and $576 million by 2028. INPEFA could be able to achieve these expectations since it is also a broad-label medication which means that it can be prescribed for an array of cardiac issues. In this way, LXRX could capitalize on a larger chunk of the market. Although there is no available information regarding profit margins, an accurate estimate regarding the company reaching profitability may not be feasible. However, if LXRX realizes revenues in line with Rahimi’s estimates, profitability may not be a far-fetched dream since the company’s costs would decrease in the coming quarters thanks to INPEFA being approved. In light of this, LXRX stock could be a bargain at the current PPS especially since the stock cooled down from its initial run on the news of INPEFA’s FDA approval. LXRX Financials According to its Q1 2023 report, LXRX’s assets declined QoQ from $194.2 million to $162.7 million which is mainly attributable to the declines in cash from $46.3 million to $26 million and short term investments from $92 million to $79.9 million. Meanwhile, liabilities decreased slightly QoQ to $74.6 million from $77.1 million. In terms of revenues, LXRX reported $24 thousand while operating costs increased YoY from $23.4 million to $31.1 million. Based on this, LXRX’s net loss widened from $23.4 million to $31.9 million. With this in mind, the company’s operating costs are expected to decrease in the future now that INPEFA is FDA approved and the expected revenues will offset LXRX’s costs. Technical Analysis LXRX stock is in a neutral trend with the stock trading in a sideways channel between its support at $2.85 and its resistance at $3.26. Looking at the indicators, LXRX stock is testing the 200 MA as support, however, it is trading below the 50 and 21 MAs. With the MACD approaching a bullish crossover, accumulation spiking, and the stock trading near its support, LXRX could be poised to rebound from current levels soon. As for the fundamentals, LXRX’s main catalyst was INPEFA’s FDA approval which allows the company to start commercializing its treatment. As the company is now set to realize its first product revenues, LXRX could climb to reflect this added value – making the current PPS an attractive entry point. LXRX Forecast With LXRX’s INPEFA receiving FDA approval, the company is now on its path to profitability as it will receive its first product revenues. Considering INPEFA’s potential in the heart failure treatments market, LXRX could be well-positioned to achieve substantial revenues that might cover its operating costs as it has other treatments in clinical trials. As the stock has cooled down from its initial run and is now trading near support, the current PPS could prove to be a good entry into LXRX stock ahead of INPEFA’s market launch in June.
NASDAQ:LXRX
by Penny_Stocks_Today
Swingtrade examples for breakoutsJust like TXMD, I like Lexicon too. BB is an indicator that even though I don't rely on, but together with RSI -and some other factors and market conditions- it's not a bad idea to consider looking at it. The vertical lines represent the buy and sell moments on this chart, please note where the price was at those points on the Bollinger Band and what value we saw on the RSI. (BTW, I bought at $1.26) So, not a rule oc, (but interesting data we have in front of us) that where with the green fat arrows I was pointing to are the prices at the lower B.band + "oversold" RSI levels, these usually result in a breakout especially if the band is contracted (called the squeeze) and the other way around similarly, when price was at the higher band + "overbought" RSI more likely than not is followed by a correction (price drop). Just an observation of a few decades. *sorry about the typos
NASDAQ:LXRX
by janfoux
LXRX - a gain again?Possibility to gain again? It looks like it want to crawl up on a support line (green). I've packed bags here a little. Indicators are almost reversed to bullish. But it still can go lower if it breaks the support line. Remember to have a stop loss below the support line. There is a big gap below 5.60. There also could happen a bear trap, quick fall and then quick retrace and skyrocketing. This one is going to be fun soon. But Reward/Risk ratio is promising. 1st target point is 7.60(+over 30% profit). fundamentally : beating almost every estimations lately. Good luck!
NASDAQ:LXRXLong
by MateuszZakrzewski
LXRX 3/10/2021Daily Chart Analysis: This stock is coming off a lengthy distribution phase between 5.99 – 20.00 which lasted around 3580 days. The price then made it downwards move and found a support @ around 1.18. Over the past 530 days, the price was in an accumulation phase between 1.18 – 4.15 and after the occurrence of a Golden Cross, a sharp breakout move upwards of 121% occurred on 1/14/21. This breakout move broke thru two resistance areas; 4.15 and most importantly 5.99. Price has since made a pullback move back to 5.99 area and bounced off that area and the 50 ema. This is very importance because the area of 5.99 was a major support level previously. This is all very bullish and exhibiting very good buyer strength. Price looks to be entering an uptrend move and with price being at a previous support level. This will be my que for entry. I will investigate the lower time frame for possible entry. 1hr Chart Anlysis: Here I will take a closer look at the break out move and its pullback for a possible entry. After the breakout move topped out at 9.40, it pulled back to 6.64 area where it then made a false breakdown move to 5.99 and rejected the lower prices and bouncing back above 6.64. At this point, price followed that move by breaking thru the downtrend trendline from the pull move. 1hr chart Entry – The price has broken out from the pullback trendline and it is currently at 7.28. I am a little hesitant to buy it right now because the price might drop a little lower. Price is also in overbought territory in the Stochastic indicator. I would like it to come down to oversold territories but I also know that during a strong move, price can remain overbought for a while price continues to climb. My current price target is 6.75. IF I enter @ 6.75, THEN I will set my stop loss at 6.50(-3.75%) and IF I get stopped out, THEN I will look to reenter @ 6.00 with stoploss @ 5.75. IF I get stopped out @ 5.75, THEN I will not be reentering this trade. I also know that the price might not come down to 6.75 and I will be ready for that. IF the price remains at the current price or falls to 7.15 and is caught and supported by the 20 and/or 50 ema, THEN I will enter trade and set my stoploss at 6.96. IF I enter at these prices and stopped at 6.96, THEN I will look to reenter at the prices mentioned above.
NASDAQ:LXRXLong
by rudcharts
$LXRX Technical ANALysis•MY Technical Analysis!! Please read it even though it's long. I am sort of new to TA. Please let me know if there are parts that are useless or suck😂 (Looking at the 14th and 15th on a 30 min time frame) -held the 25 ema even during the 15th dip, held the 20 ema all but 1 hour, it then popped up to hold all EMA's. -the last 30 minute volume on the 15th was nearly the biggest of the day. (The first 30 min time frame was the largest) -the last 4 30 min time frames were green - 6.50 held well on Friday. Acting as support right now? - drew lines from 14th's low to 15 end of day, also 14th's high to 15 end of day. Looks like crossing 7.00 is very important. Did the same idea only for the 14th's low and high's to the EOD. The points meet at 6.72, an hour and 45 minutes into Tuesdays trading. It will need to break out, down or up. - stoch RSI ended below 10, whereas RSI(14) ended at 55 ·
NASDAQ:LXRXLong
by byuipreston